|
시장보고서
상품코드
2032366
소화기계 일반의약품 시장 : 약제 클래스별, 적응증, 최종 사용자, 지역별(2026-2034년)Gastrointestinal OTC Drugs Market by Drug Class, Indication (Gastroesophageal Reflux Disease or Heartburn, Constipation, Diarrhea, Motion Sickness, and Others), End User, and Region 2026-2034 |
||||||
세계의 소화기계 일반의약품 시장 규모는 2025년에 453억 달러에 이르렀습니다. 향후 IMARC Group은 2034년까지 시장 규모가 633억 달러에 이르고, 2026-2034년 CAGR은 3.66%를 나타낼 것으로 예측했습니다. 소화기 질환의 유병률 증가, 소화기 건강에 대한 대중의 인식 증가, 최근 첨단 제제 개발 동향 등이 시장을 주도하는 주요 요인으로 작용하고 있습니다.
일반의약품(OTC 의약품)은 위장 증상을 완화하고 소화기 건강 전반을 증진시키는 처방전 없이 구입할 수 있는 의약품을 말합니다. 여기에는 완하제, 제산제, H2 차단제, 양성자 펌프 억제제(PPI), 구토제, 장용 항염증제, 설사약 등이 포함됩니다. 소화기 OTC 의약품은 소화불량, 변비, 속쓰림, 설사, 멀미, 위산 역류, 메스꺼움, 과민성 대장 증후군(IBS), 복통의 치료에 널리 사용되고 있습니다. 이 제품은 비용 효율적이고, 편리하고, 쉽게 구할 수 있으며, 즉각적인 완화 효과를 제공하고, 환자의 편안함을 향상시키고, 자가 관리를 가능하게 하는 제품입니다. 또한, 소화기계 일반의약품은 장내 환경 개선, 유익균 회복, 향후 합병증 예방, 통증, 복부 팽만감, 복부 불편감, 구토 등 다양한 증상의 심각성을 완화하는 데 도움이 됩니다.
소화기계 일반의약품 시장 동향 :
좌식 생활과 건강에 해로운 식습관으로 인한 위장병 유병률 증가는 시장 성장을 가속하는 주요 요인 중 하나입니다. 소화기계 일반의약품은 감염, 소화불량, 급성 설사, 가슴앓이, 위식도역류질환(GERD), 변비, 복부팽만감, 입덧 등의 치료에 널리 사용되고 있습니다. 또한, 소화기 건강에 대한 대중의 인식이 높아짐에 따라 소화 개선, 장내 환경 개선, 영양소의 적절한 분해 및 흡수를 보장하기 위한 제품 사용이 증가하고 있으며, 이는 시장 성장에 탄력을 받고 있습니다. 이에 따라 자신의 건강관리와 미래의 건강상 합병증을 예방하기 위한 셀프케어와 소비자의 주체성이라는 새로운 트렌드도 성장을 가속하는 요인으로 작용하고 있습니다. 또한, 발포정, 액상, 현탁액, 필름 스트립, 츄어블 제품 등 첨단 제형 개발은 약물의 효능을 높이고, 흡수율을 높이며, 투여 빈도를 줄여 시장 성장에 긍정적인 영향을 미치고 있습니다. 이 외에도 블리스터 팩, 재밀봉 가능한 파우치, 1회용 패킷 등 편리하고 휴대가 용이한 패키지의 도입도 시장 성장을 견인하고 있습니다. 이와는 별도로, 비침습적 치료법에 대한 소비자의 선호도가 높아지면서 일반적인 소화기 질환을 관리하고 즉각적인 완화를 제공하는 제품에 대한 수요가 증가하고 있습니다. 또한, TV 광고, 소셜 미디어, 인플루언서 마케팅, 유명인사 기용 등을 통한 여러 제조업체의 적극적인 홍보 및 브랜딩 캠페인이 시장 성장을 견인하고 있습니다. 기타 고령 인구 증가, 소비자의 구매력 향상, 전자상거래 플랫폼에서의 제품 구매 용이성 등의 요인도 시장 성장을 견인할 것으로 예측됩니다.
목차
제1장 서문
제2장 조사 범위와 조사 방법
제3장 주요 요약
제4장 서론
제5장 세계의 소화기계 일반의약품 시장
제6장 시장 분석 : 약제 클래스별
제7장 시장 분석 : 적응증별
제8장 시장 분석 : 최종 사용자별
제9장 시장 분석 : 지역별
제10장 성장 촉진요인, 억제요인 및 기회
제11장 밸류체인 분석
제12장 Porter's Five Forces 분석
제13장 가격 분석
제14장 경쟁 구도
KTH 26.05.15The global gastrointestinal OTC drugs market size reached USD 45.3 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 63.3 Billion by 2034, exhibiting a growth rate (CAGR) of 3.66% during 2026-2034. The rising prevalence of gastrointestinal disorders, increasing awareness among the masses regarding digestive health, and the recent development of advanced formulations represent some of the key factors driving the market.
Gastrointestinal over-the-counter (OTC) drugs refer to non-prescription medications that alleviate gastrointestinal symptoms and promote overall digestive wellness. It includes laxatives, antacids, H2 blockers, proton pump inhibitors (PPIs), anti-emetics, bowel anti-inflammatory, and anti-diarrheal medications. Gastrointestinal OTC drugs are widely used to treat indigestion, constipation, heartburn, diarrhea, motion sickness, acid reflux, nausea, irritable bowel syndrome (IBS), and abdominal pain. It is a cost-effective, convenient, and easily accessible product that provides immediate relief, enhances patient comfort, and allows self-management. Gastrointestinal OTC drugs also aid in improving gut health, restoring beneficial bacteria, preventing future complications, and minimizing the severity of various symptoms, such as pain, bloating, abdominal discomfort, and vomiting.
GASTROINTESTINAL OTC DRUGS MARKET TRENDS:
The rising prevalence of gastrointestinal disorders due to sedentary lifestyles and unhealthy eating habits is one of the key factors providing a thrust to the market growth. Gastrointestinal OTC drugs are widely used to treat infections, dyspepsia, acute diarrhea, heartburn, gastroesophageal reflux disease (GERD), constipation, bloating, and morning sickness. Furthermore, the increasing product applications to improve digestion, promote gut health, and ensure proper breakdown and absorption of nutrients, owing to the growing awareness among the masses regarding digestive health, is providing an impetus to the market growth. In line with this, the emerging trends of self-care and consumer empowerment to manage well-being and prevent future health complications are acting as another growth-inducing factor. Additionally, the recent development of advanced formulations, such as effervescent tablets, liquids, suspensions, film strips, and chewable products, which enhances the effectiveness of the drugs, increases absorption, and reduces the frequency of dosing, is positively influencing the market growth. Besides this, the introduction of convenient and travel-friendly packaging, such as blister packs, resealable pouches, and single-dose packets, is propelling the market growth. Apart from this, the rising consumer preference for non-invasive treatments is facilitating product demand to manage common digestive issues and provide immediate relief. Moreover, aggressive promotional and branding campaigns by several manufacturers through television (TV) commercials, social media, influencer marketing, and celebrity endorsement is strengthening the market growth. Other factors, including the rising geriatric populations, increasing expenditure capacities of consumers, and easy availability of products across e-commerce platforms, are anticipated to drive the market growth.
KEY MARKET SEGMENTATION:
Drug Class Insights:
- Laxatives
- Gastrointestinal Cancer Treatments
- Gastric Acid Reducers
- Anti-Diarrheal
- Proton Pump Inhibitors
- H2 Inhibitors
- Gastric Acid Neutralizers
- Bowel Anti-Inflammatory
- Anti-Emetics
Indication Insights:
- Gastroesophageal Reflux Disease (GERD) or Heartburn
- Constipation
- Diarrhea
- Motion Sickness
- Others
End User Insights:
- Hospitals
- Clinics
- Others
Regional Insights:
- North America
- United States
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for gastrointestinal OTC drugs. Some of the factors driving the North America gastrointestinal OTC drugs market included the rising prevalence of gastrointestinal disorders, increasing awareness among the masses, and various product innovations.
COMPETITIVE LANDSCAPE:
The report has also provided a comprehensive analysis of the competitive landscape in the global gastrointestinal OTC drugs market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Boehringer Ingelheim GmbH, Johnson & Johnson, Prestige Consumer Healthcare Inc., Purdue Pharma L.P, Sanofi, Zydus Lifesciences Limited, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Gastrointestinal OTC Drugs Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Drug Class
- 6.1 Laxatives
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Gastrointestinal Cancer Treatments
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Gastric Acid Reducers
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Anti-Diarrheal
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
- 6.5 Proton Pump Inhibitors
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
- 6.6 H2 Inhibitors
- 6.6.1 Market Trends
- 6.6.2 Market Forecast
- 6.7 Gastric Acid Neutralizers
- 6.7.1 Market Trends
- 6.7.2 Market Forecast
- 6.8 Bowel Anti-Inflammatory
- 6.8.1 Market Trends
- 6.8.2 Market Forecast
- 6.9 Anti-Emetics
- 6.9.1 Market Trends
- 6.9.2 Market Forecast
7 Market Breakup by Indication
- 7.1 Gastroesophageal Reflux Disease (GERD) or Heartburn
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Constipation
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Diarrhea
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Motion Sickness
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
- 7.5 Others
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
8 Market Breakup by End User
- 8.1 Hospitals
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Clinics
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Others
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.1.1 United States
- 9.2 Asia-Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.2.1 China
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.3.1 Germany
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.4.1 Brazil
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 Drivers, Restraints, and Opportunities
- 10.1 Overview
- 10.2 Drivers
- 10.3 Restraints
- 10.4 Opportunities
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 Boehringer Ingelheim GmbH
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.1.3 SWOT Analysis
- 14.3.2 Johnson & Johnson
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.2.3 Financials
- 14.3.2.4 SWOT Analysis
- 14.3.3 Prestige Consumer Healthcare Inc.
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.3.3 Financials
- 14.3.3.4 SWOT Analysis
- 14.3.4 Purdue Pharma L.P
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.5 Sanofi
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.5.3 Financials
- 14.3.5.4 SWOT Analysis
- 14.3.6 Zydus Lifesciences Limited
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.6.3 Financials
- 14.3.6.4 SWOT Analysis
- 14.3.1 Boehringer Ingelheim GmbH
